Parse Biosciences

Single-cell analysis tools and software

Seattle, Washington, United States

About Parse Biosciences

Parse Biosciences focuses on advancing single-cell research by providing solutions that allow scientists to analyze individual cells with high precision. Their technology, known as "split-pool combinatorial barcoding," enables scalable single-cell analysis without the need for costly custom instruments. The company offers an end-to-end solution that includes preparing cell or nuclei suspensions, sequencing, and data analysis, all supported by their proprietary software, Trailmaker. Unlike competitors, Parse Biosciences emphasizes accessibility and scalability in their products, making advanced single-cell analysis available to a wider range of researchers and institutions. The company's goal is to push the boundaries of single-cell science and support researchers in exploring new areas of inquiry.

Seattle, WashingtonHeadquarters
2018Year Founded
$72.7MTotal Funding
SERIES_CCompany Stage
Data & Analytics, BiotechnologyIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
Company Equity
Paid Holidays
Paid Vacation
Hybrid Work Options

Risks

Competition from 10x Genomics could impact Parse Biosciences' market share.
Rapid technological advancements may render current technology obsolete.
Potential intellectual property disputes in the competitive single-cell sequencing field.

Differentiation

Parse Biosciences uses combinatorial cDNA barcoding to eliminate microfluidic instruments.
Their technology allows fixed samples to be stored and processed later.
Parse's Trailmaker software offers end-to-end solutions for single-cell analysis.

Upsides

Expansion of Evercode product line enhances immune repertoire research capabilities.
GigaLab launch scales single-cell sequencing to billions of cells annually.
Partnership with Vevo Therapeutics integrates AI with biotechnology for drug discovery.

Funding

Total raised$72.66 M
Latest valuation$207.50 M
StageSERIES_C